SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

A sharp, apparently newsless XCN spike is driving attention, with traders debating whether it is a fleeting pump-and-dump or a rebound worth buying. Some point to Bitcoin turning green and bullish chart patterns, while others cite XCNs history of quick spikes followed by drops.

Papa John's International, Inc. engages in the operation and franchise of pizza delivery and carryout restaurants. It operates through the following segments: Domestic Company-owned Restaurants, North America Franchising, North America Commissaries, International Operations, and All Others. The Domestic Company-Owned Restaurants segment consists of retail sales of pizza and side items, breadsticks, cheese sticks, chicken poppers and wings, dessert items, and canned and bottled beverages. The North America Franchising segment involves the offering of sales and support activities, development rights, and collection of royalties from franchisees located in the United States and Canada. The North America Commissaries segment includes the eleven full-service regional dough production and distribution and quality control centers. The International Operations segment represents all restaurant operations outside of the United States and Canada. The All Others segment focuses on franchise contributions to marketing funds and sale, company-owned and franchised restaurants, information systems and related services used in restaurant operations, point-of-sale system, online and other technology-based ordering platforms, printing, and promotional items. The company was founded by John H. Schnatter in 1984 and is headquartered in Louisville, KY.

Papa John`s International, Inc.

Attention centers on reports that Papa Johns largest U.S. franchisee has joined Irth Capitals effort to take the company private. Traders are hopeful a deal could materialize, but uncertainty over the boards response and whether the bid will close remains a point of debate.

MaxLinear, Inc. engages in the provision of communications systems-on-chip (SoC) solutions used in broadband, mobile and wireline infrastructure, data center, and industrial and multi-market applications. Its products include cable broadband modems and gateways, wireline connectivity devices, radio frequency transceivers, fiber-optic modules, video set-top boxes and gateways, hybrid analog and digital televisions, direct broadcast satellite outdoor and indoor units, and power management and interface products. The company was founded by Kimihiko Imura, Curtis C. Ling, and Kishore V. Seendripu on September 25, 2003 and is headquartered in Carlsbad, CA.

MaxLinear Inc

A beat-and-raise quarterly report and a third increase to MaxLinears 2026 optical data-center outlook are reinforcing its AI optics growth story. Traders are divided as the shares fall despite the strong update, citing higher expectations, cash-flow concerns, and competition in high-speed interconnects.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Phase 3 results showing IMDELLTRA plus Imfinzi reduced the risk of death in first-line extensive-stage small-cell lung cancer are driving discussion, with traders viewing the data as a potential growth catalyst for Amgens oncology business. Some also point to Repathas growth as support for the companys broader portfolio.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

Discussion centers on volatile Dow and broader-market moves amid rising Treasury yields, hawkish Fed concerns, and oil and geopolitical risks tied to Iran. Traders are divided between warnings of a deeper selloff and bullish calls for a rebound, with some noting the Dows relative strength versus tech-heavy indexes.

Permian Resources Corp. is an oil and natural gas company, which focuses on returns to stakeholders through the responsible acquisition, optimization and development of crude oil and associated liquids-rich natural gas reserves. The company was founded on December 18, 2025 and is headquartered in Midland, TX.

Permian Resources Holdings Inc. - Ordinary Shares - Class A

Permian Resources Corp - Ordinary Shares - Class A

Permian Resources is drawing attention amid volatile oil prices and Middle East supply concerns, especially disruptions and uncertainty around the Strait of Hormuz and Iran negotiations. Bulls see elevated crude and the companys production growth as supportive, while skeptics point to peace-deal headlines, inventory concerns, and the stocks uneven response to oil moves.

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

Agenuss BOT+BAL colorectal cancer results are driving discussion, with traders highlighting tumor responses and the possibility of organ preservation while questioning whether small, nonrandomized studies will translate into durable benefit. Optimism about the treatments potential is tempered by concerns over Phase 3 timing, dilution, and management execution.

FMC Corp. is an agricultural sciences company, which engages in the provision of solutions to growers and development of pipeline in crop protection, plant health, agriculture, pest control, and turf management. It offers insect control products under the Rynaxypyr and Cyazypyr brands. The company was founded by John Bean in 1883 and is headquartered in Philadelphia, PA.

FMC Corp.

FMCs sharp outlook reset, driven by price cuts on distributor-held inventory and weak demand, is fueling concern about its business outlook and debt burden. Traders are split between fears of further financial distress and the view that the inventory reset and debt-reduction efforts could support a longer-term turnaround.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

Uniteds quarterly results and weaker-than-expected profit outlook have focused attention on rising jet-fuel costs and pressure on margins, despite strong revenue and travel demand. Traders are split between concern over the guidance and optimism that resilient bookings and a recent share-price rebound may offset the bad news.

Six Flags Entertainment Corp. engages in operating amusement parks in North America. It operates amusement parks, water parks, and resorts. The company is headquartered in Charlotte, NC.

Six Flags Entertainment Corp.

Six Flags Entertainment Corp

Shares are under pressure amid fallout from a fatal accident on Six Flags Goliath coaster, with traders concerned about ride closures, the safety investigation, potential lawsuits and reputational damage. The discussion also centers on heavy debt and bearish analyst views, while some traders argue the selloff and high short interest could set up a rebound.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?

Ultragenyx's established rare-disease treatments continue to support revenue growth, while two newly approved gene therapies offer additional commercial opportunities.

Klotho Protein Emerges as a Potential Powerhouse In the Next Generation of Longevity Medicine

Human clinical development is putting one of aging biology’s most closely watched proteins on the biotechnology radar   New York, NY – September 30, 2026 – Klotho is quickly becoming one of the more interesting names in longevity research. What started largely as a research question around aging and biological decline is now moving closer […]
The post Klotho Protein Emerges as a Potential Powerhouse In the Next Generation of Longevity Medicine appeared first on Financial News Media.

DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?

Denali's Avlayah launch drives strong uptake and a 33.1% three-month stock gain, but regulatory and pipeline risks remain.

Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?

BIIB's newer drugs, M&A activity and pipeline progress are fueling its turnaround, but declining MS sales remain a key risk.

Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum

Denali Therapeutics narrows Q2 loss as Avlayah sales top estimates, with strong launch traction and pipeline updates shaping its outlook.

Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates

Denali Therapeutics (DNLI) delivered earnings and revenue surprises of +5.56% and +143.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Will Recent Setbacks Impact Growth Prospects of DNLI Stock?

Denali Therapeutics gains FDA approval for Avlayah, but pipeline setbacks and partner exits raise fresh questions as key clinical programs continue.

DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth?

Denali Therapeutics surges on Avlayah???s FDA approval, PRV sale and pipeline progress, but partnership changes and trial setbacks remain in focus.

Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS II

RGNX shares jump after FDA alignment on next steps for Navsunli, paving the way for a planned MPS II BLA resubmission in Q3 2026.

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Denali Therapeutics Inc

BIIB, DNLI Stocks Edge Lower After Hours: Parkinson’s Drug Misses Key Goals In Trial

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Despite the miss, the companies said the medicine was generally well tolerated with an acceptable safety profile and demonstrated strong target engagement in the body.</li><li>Biogen and Denali will stop further development of BIIB122 for the broader idiopathic form of Parkinson’s.&nbsp;</li><li>Denali will continue its separate early-to-middle BEACON study of the same drug, but only in the smaller group of patients who carry a specific genetic mutation.</li></ul>Shares of Biogen Inc. (BIIB) slipped about 1% in after-hours trading on Thursday after the company and partner Denali Therapeutics (DNLI) announced that their mid-stage LUMA study of an experimental Parkinson’s disease drug failed to meet its primary and secondary goals.&nbsp;DNLI stock, meanwhile, fell 7% after hours.&nbsp;The late-stage trial tested BIIB122, also known as DNL151, a small-molecule pill designed to block overactive LRRK2 — a protein linked to Parkinson’s — in hopes of slowing disease progression in people with early-stage idiopathic Parkinson’s. The study did not show that the drug slowed the worsening of motor and daily-living symptoms compared with placebo, as measured by a standard Parkinson’s rating scale.Parkinson's Disease is a progressive neurological disorder caused by the loss of dopamine-producing neurons in the brain. It leads to unintended movement issues, as well as non-motor symptoms like cognitive impairment, depression, and sleep problems.<h2 class="st-heading-2">What Next For The Experimental Therapy?</h2>Despite the miss, the companies said the medicine was generally well tolerated with an acceptable safety profile and demonstrated strong target engagement in the body. As a result, Biogen and Denali will stop further development of BIIB122 for the broader idiopathic form of Parkinson’s.Denali will continue its separate early-to-middle BEACON study of the same drug, but only in the smaller group of patients who carry a specific genetic mutation that over-activates LRRK2. Results from that trial are expected in the first half of 2027.“While these are not the results we hoped for, these data provide important information to the Parkinson’s community and will be presented at an upcoming scientific conference,” said Diana Gallagher, Senior Vice President and Head of Neurodegeneration Clinical Development at Biogen.Peter Chin, Chief Medical Officer at Denali Therapeutics, added that the companies will analyze the full data set alongside upcoming BEACON results to decide next steps.<h2 class="st-heading-2">How Did DNLI, BIIB Retail Traders React?</h2>On Stocktwits, retail sentiment around BIIB and DNLI stocks were ‘bearish’ at the time of writing, coupled with ‘high’ message volume.While <a href="https://stocktwits.com/symbol/BIIB">BIIB stock</a> has gained 49% over the past 12 months, <a href="https://stocktwits.com/symbol/DNLI">DNLI</a> added 41%.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/imax-stock-soars-after-hours-following-news-of-early-stage-sale-process/cZXCS88Re8Z">IMAX Stock Soars After Hours Following News Of Early-Stage Sale Process</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration the logo of Biogen is seen on a smartphone with the FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)  

The study did not show that the drug slowed the worsening of motor and daily-living symptoms compared with placebo, the company said. 

Biogen Inc

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$18.41
Prev Close	$18.66
Open	$18.49
Dividend Yield	0.00%
50-Day Moving Average	$21.21
Beta	1.67
Avg. Volume	1.77M
PE Ratio	-6.49

52-Week High	$27.30
52-Week Low	$13.75
Market Capitalization	$2.94B
EPS (Annual)	-$2.97
Price to Book	3.52
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

DNLI Fundamentals